Oxford Immunotec Global PLC
DelistedCIK 1586049fmd_02V48S4WHB4T8TZXCFKZM1PBB5Manufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2020, 32 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 21 | 39 | 50 | 63 | 47 | 55 | 60 | 74 |
| Cost of revenue | 12 | 19 | 24 | 30 | 16 | 18 | 17 | 19 |
| Net interest income | (1) | (0) | (0) | (0) | (1) | (3) | (2) | 4 |
| Gross profit | 8 | 20 | 25 | 33 | 30 | 36 | 43 | 54 |
| Research and development | 2 | 2 | 7 | 10 | 9 | 11 | 8 | 9 |
| Selling, general and administrative | 19 | 25 | 40 | 46 | 46 | 55 | 52 | 51 |
| Total operating expenses | 21 | 28 | 47 | 57 | 56 | 90 | 64 | 61 |
| Operating income | (13) | (7) | (22) | (24) | (25) | (54) | (21) | (6) |
| Other non-operating income (expense) | – | (0) | 0 | 0 | (1) | (0) | (0) | 0 |
| Income before taxes | (15) | (9) | (22) | (24) | (25) | (32) | (25) | (4) |
| Income tax expense | (0) | 0 | 0 | 0 | (4) | 2 | (37) | (2) |
| Net income from continuing operations | (15) | (9) | (22) | (24) | (22) | (33) | 13 | (1) |
| Net income | (15) | (9) | (22) | (24) | (22) | (33) | 121 | (2) |